Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
US Department of Justice
Fuji
Fish and Richardson
Argus Health
QuintilesIMS

Generated: May 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,076,505

« Back to Dashboard

Which drugs does patent 10,076,505 protect, and when does it expire?

Patent 10,076,505 protects REMODULIN and is included in two NDAs.

This patent has thirteen patent family members in nine countries.

Summary for Patent: 10,076,505
Title:Inhalation formulations of Treprostinil
Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
Inventor(s): Wade; Michael (Chapel Hill, NC)
Assignee: United Therapeutics Corporation (Silver Spring, MD)
Application Number:15/657,933
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 10,076,505
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 10,076,505

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-001 May 21, 2002 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-002 May 21, 2002 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-003 May 21, 2002 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-004 May 21, 2002 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
United Therap REMODULIN treprostinil SOLUTION;INTRAVENOUS, SUBCUTANEOUS 208276-001 Jul 30, 2018 RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
McKinsey
Boehringer Ingelheim
Queensland Health
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.